AGN has been the topic of several other reports. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the company a buy rating in a report on Thursday, June 8th. Sanford C. Bernstein reiterated an outperform rating on shares of Allergan PLC. in a report on Thursday, May 25th. Mizuho reduced their target price on Allergan PLC. from $275.00 to $267.00 and set a buy rating on the stock in a report on Friday, June 9th. Royal Bank Of Canada reiterated a buy rating and issued a $285.00 target price on shares of Allergan PLC. in a report on Wednesday, September 6th. Finally, Cantor Fitzgerald initiated coverage on Allergan PLC. in a report on Friday, June 16th. They issued a neutral rating and a $231.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. Allergan PLC. has a consensus rating of Buy and a consensus price target of $274.69.
Shares of Allergan PLC. (AGN) opened at 220.29 on Tuesday. The company has a 50 day moving average of $231.75 and a 200-day moving average of $236.59. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The firm has a market capitalization of $73.64 billion, a P/E ratio of 6.71 and a beta of 1.18.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the prior year, the business posted $3.35 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. Analysts predict that Allergan PLC. will post $16.25 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Allergan PLC. by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after purchasing an additional 482,220 shares during the period. Northern Trust Corp raised its position in shares of Allergan PLC. by 8.8% during the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after purchasing an additional 364,722 shares during the period. Veritas Asset Management LLP acquired a new position in shares of Allergan PLC. during the first quarter worth approximately $761,339,000. Edgewood Management LLC raised its position in shares of Allergan PLC. by 7.0% during the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after purchasing an additional 178,055 shares during the period. Finally, Epoch Investment Partners Inc. raised its position in shares of Allergan PLC. by 3.8% during the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after purchasing an additional 73,081 shares during the period. 82.06% of the stock is currently owned by institutional investors.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.